Pharsight

Tersera patents expiration

1. Prialt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5795864 TERSERA Stable omega conopetide formulations
Jun, 2015

(8 years ago)

US5364842 TERSERA Method of producing analgesia
Dec, 2016

(7 years ago)

US8765680 TERSERA Method for administering omega-conopeptide
Oct, 2024

(3 months from now)

US8653033 TERSERA Method for administering omega-conopeptide
Oct, 2024

(3 months from now)

US9707270 TERSERA Method for administering ω-conopeptide
Oct, 2024

(3 months from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Market Authorisation Date: 28 December, 2004

Treatment: Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage

PRIALT family patents

Family Patents

2. Qmiiz Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879 TERSERA Fast disintegrating compositions of meloxicam
Aug, 2030

(6 years from now)

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 19 October, 2018

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

QMIIZ ODT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Varubi patents expiration

VARUBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7049230 TERSERA Method of forming a contact plug in a semiconductor device
Dec, 2023

(6 months ago)

US8178550 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Apr, 2027

(2 years from now)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists
Dec, 2022

(1 year, 5 months ago)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US7563801 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
Apr, 2027

(2 years from now)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Jan, 2029

(4 years from now)

US8361500 TERSERA Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
Oct, 2029

(5 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 01, 2020

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

NCE-1 date: 02 September, 2019

Market Authorisation Date: 25 October, 2017

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

VARUBI family patents

Family Patents

4. Xermelo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7553840 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(3 years from now)

US8193204 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Feb, 2031

(6 years from now)

US7709493 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Feb, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559 TERSERA Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
Dec, 2027

(3 years from now)

US8653094 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-132) Feb 28, 2024
Orphan Drug Exclusivity(ODE) Feb 28, 2024
New Chemical Entity Exclusivity(NCE) Feb 28, 2022

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

NCE-1 date: 28 February, 2021

Market Authorisation Date: 28 February, 2017

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

More Information on Dosage

XERMELO family patents

Family Patents

5. Zoladex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500964 TERSERA Automatically operable safety shield system for syringes
Feb, 2021

(3 years ago)

US7220247 TERSERA Automatically operable safety shield system for syringes
Apr, 2022

(2 years ago)

US7118552 TERSERA Automatically operable safety shield system for syringes
Apr, 2022

(2 years ago)

Drugs and Companies using GOSERELIN ACETATE ingredient

Market Authorisation Date: 11 January, 1996

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

ZOLADEX family patents

Family Patents